Mobile

A Phase II Randomised, Double-blind, Placebo-controlled, Multicentre Comparative study of ZD1839 250 mg or 500 mg (Iressatm) given either continuously or concomitantly with cisplatin plus radiotherapy...

Mise à jour : Il y a 4 ans
Référence : EUCTR2004-000358-21

A Phase II Randomised, Double-blind, Placebo-controlled, Multicentre Comparative study of ZD1839 250 mg or 500 mg (Iressatm) given either continuously or concomitantly with cisplatin plus radiotherapy for the treatment of patients with previously untreated unresected late stage III/IV non-metastatic head and neck squamous cell carcinoma

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

The primary objective of the study is to assess the additive effect of ZD1839 250 mg and ZD1839 500 mg (given either concomitantly or as maintenance) over cisplatin plus radiotherapy (RT) in terms of local disease control (progression-free) rate at 2 years.

Critère d'inclusion

  • Untreated, unresected late stage III/IV non-metastatic head and neck squamous cell carcinoma

Liens